Building on these insights, the phase 3 ATTLAS trial further evaluated the efficacy of atezolizumab in combination with bevacizumab and chemotherapy (ABCP) against the standard pemetrexed plus carboplatin or cisplatin in EGFR or ALK-mutated NSCLC who experienced progression following prior TKI therapy. Here, ALK is linked to non-small cell lung carcinoma.